U.S. Markets closed

Endo International plc (ENDP)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.38+0.06 (+0.49%)
At close: 4:00PM EDT

12.34 -0.04 (-0.32%)
After hours: 6:27PM EDT

People also watch
VRXMYLPRGOALXNHZNP

Endo International plc

Minerva House
First Floor
Dublin 4
Ireland
353 1 268 2000
http://www.endo.com

SectorHealthcare
IndustryDrug Manufacturers - Other
Full Time Employees4,894

Key Executives

NameTitlePayExercisedAge
Mr. Paul V. CampanelliChief Exec. Officer, Pres and Director1.72MN/A55
Mr. Blaise ColemanChief Financial Officer and Exec. VP676.69kN/A43
Mr. Terrance J. CoughlinChief Operating Officer and Exec. VP879.57kN/A51
Mr. Matthew Joseph MalettaChief Legal Officer and Exec. VP746.43kN/A45
Mr. Daniel A. RudioChief Accounting Officer, Sr. VP and ControllerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and cardiovascular disease markets. The company’s U.S. Branded Pharmaceuticals segment offers pain management products, such as Lidoderm, OPAN ER, Percocet, and Voltare Gel. This segment also provides Supprelin LA for central precocious puberty treatment; XIAFLEX for treating Peyronie’s and Dupuytren’s contracture diseases; Fortesta Gel for hypogonadism treatment; Testim Gel for the treatment of endogenous testosterone; Frova for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; Vantas for the palliative treatment of advanced prostate cancer; Aveed for the treatment of low testosterone; TESTOPEL, a long-acting implantable pellet; and NASCOBAL, a nasal spray. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, women’s health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Corporate Governance

Endo International plc’s ISS Governance QualityScore as of July 1, 2017 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.